Virtu Financial’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Virtu Financial’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-262,020	Closed	-$411K	–	2445
2022 Q3	$411K	Buy	262,020 +58,357	+29%	+$132K	0.04%	492
2022 Q2	$409K	Buy	+203,663	New	+$352K	0.03%	448
2021 Q2	–	Sell	-113,385	Closed	-$938K	–	2274
2021 Q1	$938K	Sell	113,385 -148,410	-57%	-$1.57M	0.07%	276
2020 Q4	$1.79M	Buy	+261,795	New	+$2.1M	0.19%	125
2019 Q4	$303K	Buy	+89,749	New	+$214K	0.03%	675
2019 Q3	–	Sell	-43,041	Closed	-$115K	–	1970
2019 Q2	$115K	Buy	43,041 +14,224	+49%	+$51.2K	0.01%	1116
2019 Q1	$137K	Sell	28,817 -40,692	-59%	-$107K	0.01%	1081
2018 Q4	$167K	Buy	69,509 +16,202	+30%	+$52.9K	0.01%	1019
2018 Q3	$235K	Buy	+53,307	New	+$296K	0.01%	994
2018 Q2	–	Sell	-31,083	Closed	-$160K	–	2646
2018 Q1	$160K	Buy	+31,083	New	+$221K	0.01%	1445
2017 Q4	–	Sell	-43,348	Closed	-$74K	–	3183
2017 Q3	$74K	Buy	43,348 +29,258	+208%	+$53.7K	﹤0.01%	2148
2017 Q2	$28K	Buy	+14,090	New	+$27.5K	﹤0.01%	371

Other funds holding SRNE

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BRF

B. Riley Financial Los Angeles, California $434M AUM 751.56% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Virtu Financial's SRNE Position: Q4 2022 in Review

Virtu Financial sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2022, closing a stake of 262,020 shares — an estimated $411K sold.

Virtu Financial first reported a position in SRNE in Q2 2017 and held it in 12 quarters. The position peaked at $1.79M in Q4 2020. 221 funds tracked by Wall St. Rank hold SRNE as of Q4 2022.

Virtu Financial reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Virtu Financial sold 262,020 Sorrento Therapeutics, Inc. shares in Q4 2022, an estimated $411K.
Virtu Financial first reported a position in Sorrento Therapeutics, Inc. in Q2 2017 and held it in 12 quarters.
Virtu Financial's Sorrento Therapeutics, Inc. position peaked at $1.79M in Q4 2020.
221 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2022.

Based on Virtu Financial's 13F filing for Q4 2022, filed 15 Feb 2023.